In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Michał NowackiDepartment of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland.ORCID 0000-0002-3777-0119 Filipe MenezesInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.ORCID 0000-0002-7630-5447 Başak DağdevirenDepartment of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland.
Federico BallabioInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.ORCID 0000-0001-5702-3674 Valeria NapolitanoInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.ORCID 0000-0002-6709-8263 Chethan K KrishnaInstitute of Biochemistry and Pathobiochemistry, Department of Systems Biochemistry, Faculty of Medicine, Ruhr-University Bochum, 44780 Bochum, Germany.ORCID 0009-0002-3161-4075 Vishal C KalelInstitute of Biochemistry and Pathobiochemistry, Department of Systems Biochemistry, Faculty of Medicine, Ruhr-University Bochum, 44780 Bochum, Germany.
Ralf ErdmannInstitute of Biochemistry and Pathobiochemistry, Department of Systems Biochemistry, Faculty of Medicine, Ruhr-University Bochum, 44780 Bochum, Germany.
Michael SattlerInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Grzegorz M PopowiczInstitute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.ORCID 0000-0003-2818-7498 Maciej DawidowskiDepartment of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland.ORCID 0000-0002-7262-5718 Funding
Bundesministerium für Bildung und Forschung PEXMEDDeutsche Forschungsgemeinschaft Transregio 387Narodowe Centrum Nauki 2018/31/B/NZ7/02089Ruhr University Bochum, InnovationsFoRUM Host Microbe Interactions: IF-009N-22 and IF-018N-22
6 · The paper itselfAbstract
Modulation of protein-protein interactions (PPIs) by small molecules is a vital strategy in drug discovery. Nevertheless, due to the inherent nature of PPI interfaces, practical implementation of this approach remains a high-hanging fruit in medicinal chemistry. In this report, we develop a new line of PEX14-PEX5 PPI inhibitors by homologation of a previously developed dibenzo[
Indexed as
Trypanocidal AgentsDrug DesignModels, MolecularPeroxisome-Targeting Signal 1 ReceptorProtein BindingProtozoan ProteinsStructure-Activity RelationshipTrypanosoma brucei bruceiPeroxisome-Targeting Signal 1 ReceptorProtozoan ProteinsTrypanocidal Agentsantiparasitic agentsbenzo[b]pyrido[2,3-f]azocin-5(6H)-onedibenzo[b,f]azocin-6(5H)-oneprotein–protein interaction inhibitorsquantum mechanical energy decomposition and deconvolution analysisstructure-based drug design
Identifiers
PMID42794429
PMCPMC13606207
What OpenQuestion holds
Textmetadata
Read underepoch 390